Journal
MOLECULAR CANCER RESEARCH
Volume 19, Issue 4, Pages 565-572Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1541-7786.MCR-20-0985
Keywords
-
Categories
Funding
- NIH-NCI [R21CA218933, R01CA212600-01]
- NIH [U01CA224012, P30CA069533, P30CA056036]
- Pancreatic Cancer Cure Foundation
- Pancreatic Cancer Action Network-AACR Research Acceleration Network Grant [15-90-25-BROD]
- Richard Alan Parry Pancreatic Cancer Research Fund
Ask authors/readers for more resources
CF10 is a novel drug for treating PDAC, more potent than 5-FU, effective in inhibiting PDAC cell survival by inhibiting TS and strong Top1 cleavage complex formation, and shows single-agent activity in murine models.
AraC-FdUMP[10] (CF10) is a second-generation polymeric fluoropyrimidine that targets both thymidylate synthase (TS), the target of 5-fluorouracil (5-FU), and DNA topoisomerase 1 (Top1), the target of irinotecan, two drugs that are key components of FOI,FIRNOX, a standard-of-care regimen for pancreatic ductal adenocarcinoma (PDAC). We demonstrated that F10 and CF10 are potent inhibitors of PDAC cell survival (in multiple cell lines including patient-derived lines) with IC(50)s in the nanomolar range and are nearly 1,000-fold more potent than 5-FU. The increased potency of CF10 relative to 5-FU correlated with enhanced TS inhibition and strong Top1 cleavage complex formation. Furthermore, CF10 displayed single-agent activity in PDAC murine xenografts without inducing weight loss. Through a focused drug synergy screen, we identified that combining CF10 with targeting the DNA repair enzyme, poly (ADP-ribose) glycohydrolase, induces substantial DNA damage and apoptosis. This work moves CHO closer to a clinical trial for the treatment of PDAC. [GRAPHICS] .
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available